Investment Rating - The report maintains a "Buy" rating for the company [2][8]. Core Insights - The company is expected to secure another steering-by-wire (SBW) contract by Q4 2025, indicating a stable operational outlook [2][8]. - The Asia-Pacific region is a strong growth driver, with multiple R-EPS (Rack-EPS) entering mass production in Q3 2025, contributing to an estimated $5 billion in orders for the year [8]. - The company has already received a steering-by-wire contract from a global leader in electric vehicles, supporting L4 autonomous driving and mobility as a service [8]. - An innovative direct-drive steering feel simulator has been launched, enhancing steering feel simulation and supporting compact, lightweight designs [8]. Financial Summary - Revenue projections are as follows: - 2023: $4.207 billion - 2024: $4.276 billion (up 2%) - 2025: $4.600 billion (up 8%) - 2026: $4.893 billion (up 6%) - 2027: $5.330 billion (up 9%) [7][8]. - Net profit is expected to grow significantly from $37 million in 2023 to $250 million by 2027, reflecting a 147% increase in 2025 [7][8]. - The company’s PE ratio is projected to decrease from 63.33 in 2023 to 8.67 by 2027, indicating improved valuation metrics over time [7][8]. Valuation and Target Price - The target price has been raised to HKD 9.45 for 2025, based on a 20x PE ratio [8]. - The report suggests that the company’s EPS forecasts for 2025-2027 are $0.06, $0.08, and $0.10 respectively [8].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][7]. Core Insights - The company is positioned as a high-end residential developer with a focus on premium commercial assets, anticipating a revaluation of its quality IP [6][7]. - The company is expected to achieve significant revenue growth, with projected revenues of HKD 19.5 billion in 2024, representing a year-on-year increase of 49% [6]. - The financial outlook includes a forecasted net profit of HKD 1.75 billion in 2025, reflecting a substantial year-on-year growth of 116% [6][7]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: HKD 13.09 billion - 2024: HKD 19.5 billion - 2025E: HKD 20.17 billion - 2026E: HKD 15.08 billion - 2027E: HKD 24.44 billion - Year-on-year growth rates for revenue are projected at -10.3% for 2023, 49.0% for 2024, and 3.5% for 2025 [5]. - The net profit forecast is as follows: - 2023: HKD 3.24 billion - 2024: HKD 0.81 billion - 2025: HKD 1.75 billion - 2026: HKD 1.62 billion - 2027: HKD 4.03 billion - The projected net profit growth rates are 17.7% for 2023, 75.1% for 2024, and 116.1% for 2025 [5][6]. Business Structure - The company operates a diversified business model with revenue contributions from property development (66%), IP leasing (25%), and hotel operations (9%) [6][27]. - The geographical revenue distribution shows a focus on mainland China (66%) and Hong Kong (34%) [6][27]. Property Development - The company achieved a sales amount of HKD 16.2 billion in the first half of 2025, a year-on-year increase of 130%, with mainland sales contributing HKD 10.6 billion [6][42]. - The company is focusing on high-end residential projects, particularly in Shanghai and Hong Kong, with significant sales from the Jinling Huating project [6][45]. IP and Hotel Operations - The company’s IP value reached HKD 86.3 billion in the first half of 2025, with a year-on-year increase of 14% [6]. - The total area of IP and hotel operations is projected to increase by 36% by 2031, with a compound annual growth rate (CAGR) of 7% [6][7]. Financial Health and Dividends - The company maintains a healthy financial position with a net debt ratio of 38.4% as of the first half of 2025, expected to decrease to around 30% by the end of 2026 [6]. - The company has consistently provided dividends, with a dividend per share (DPS) of HKD 1.35 since 2017, resulting in a high dividend yield of 6.9% [6][7].

Investment Rating - The report assigns a "Buy" rating to Sinofert Holdings, with a target price of HKD 1.84 based on a PE of 8.5x for FY26 [3][13]. Core Insights - In the first three quarters of 2025, Sinofert Holdings achieved a net profit of approximately CNY 1.364 billion, reflecting a year-on-year increase of 6% despite challenges such as high raw material costs and declining synthetic ammonia market prices [1][15]. - The company is actively promoting its "Bio+" strategy, which focuses on the development and innovation of biological products, resulting in significant sales growth of high-end biological fertilizers [2][12]. - A memorandum of cooperation was renewed with the Jordanian Arab Potash Company (APC) for the period 2026-2028, enhancing the strategic partnership and ensuring stable supply of potash fertilizers in China [1][15]. Financial Performance and Forecast - The projected net profits for Sinofert Holdings from 2025 to 2027 are CNY 1.263 billion, CNY 1.384 billion, and CNY 1.547 billion, respectively, indicating a positive growth trajectory [3][4]. - The company's operating revenue is expected to grow from CNY 212.65 billion in 2024 to CNY 267.23 billion by 2027, with a compound annual growth rate of approximately 9% [4][9]. - The earnings per share (EPS) is forecasted to increase from CNY 0.15 in 2024 to CNY 0.22 in 2027, reflecting the company's improving profitability [4][9].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 91.08 [1][5]. Core Insights - The Phase I clinical results of CM512, a dual antibody targeting TSLP/IL-13 for treating atopic dermatitis (AD), show promising efficacy and safety, outperforming the placebo group significantly [2][3]. - CM512 demonstrates a long half-life of 70 days, indicating potential for extended dosing intervals, and has shown rapid onset of action with a 50% EASI-75 response at 6 weeks in the 300mg dose group [2][4]. - The clinical data suggests that CM512 has competitive advantages over current standard therapies and other monoclonal antibodies, particularly in achieving deep remission [3][4]. Summary by Sections Clinical Results - The Phase I trial included 64 healthy participants and 46 moderate to severe AD patients, showing comparable rates of treatment-emergent adverse events (TEAE) and serious adverse events (SAE) between the trial and control groups [2]. - The 300mg dose group achieved EASI-75/90 rates of 58.3% and 41.7% at 12 weeks, significantly better than the placebo's 21.4% and 0% [2][3]. Competitive Landscape - CM512's EASI-90 response rate of 41.7% is superior to other treatments, including IL-4Rα monoclonal antibodies and small molecule drugs, indicating its potential as a best-in-class (BIC) therapy [3][4]. - Comparatively, other therapies like dupilumab and lebrikizumab have lower EASI-90 rates, reinforcing CM512's competitive edge [3][4]. Future Development - The company is expanding CM512's indications beyond AD, with ongoing Phase II trials for asthma, COPD, and chronic spontaneous urticaria, leveraging its long-acting profile [4]. - The potential for collaboration and further development in international markets is promising, given the initial efficacy data and competitive advantages [4]. Financial Projections - Revenue forecasts for the company have been adjusted, with expected revenues of RMB 570.96 million in 2025 and RMB 1,554 million by 2027, reflecting a significant growth trajectory [5][9]. - Net profit estimates for 2025-2027 have been revised to -679.40 million, -669.87 million, and -282.40 million respectively, indicating ongoing investment in R&D and market expansion [5][11].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company demonstrated resilience in operations with a steady same-store sales growth and effective cost management, leading to a solid performance in Q3 2025 [1][2] Financial Performance - Q3 2025 revenue reached $3.2 billion, a year-over-year increase of 4%, while operating profit was $400 million, up 8% year-over-year, slightly exceeding Bloomberg consensus estimates [1] - The operating profit margin improved to 12.5%, reflecting a 0.4 percentage point increase year-over-year [1][2] - The net profit attributable to shareholders was $282 million, down 5% year-over-year, primarily due to a decline in Meituan's stock price; excluding investment losses, net profit increased by 7% year-over-year [1] Store Expansion and Brand Performance - The company added a record 536 new stores in Q3, with a total of 17,514 stores by the end of the quarter, including 12,640 KFC and 4,022 Pizza Hut locations [3] - The same-store sales growth for KFC was 2%, while Pizza Hut saw a 1% increase, with delivery sales growing by 32% year-over-year [2][3] Shareholder Returns - The company returned a total of $414 million to shareholders in Q3, with a total of $950 million returned in the first three quarters of 2025 [4] - The company plans to return approximately $1.5 billion to shareholders for the full year, maintaining guidance for $3 billion in shareholder returns for 2025-2026 [4] Profit Forecast and Valuation - The report adjusts the company's net profit forecasts for 2025-2027 to $908 million, $986 million, and $1.049 billion, respectively, reflecting a slight downward revision [5] - The target price is adjusted to HKD 413.59, corresponding to a 2026 PE ratio of 18 times [5]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [6]. Core Insights - The company leverages gene editing technology to create a comprehensive antibody drug development platform, focusing on innovative solutions [2][16]. - The company has shown significant revenue growth, with a projected revenue CAGR of over 40% from 2021 to 2024, and is expected to turn profitable in 2024 [28][30]. - The antibody development business is a key driver of growth, with a revenue CAGR of 53% from 2021 to 2024 [5][34]. Summary by Sections Company Overview - Established in 2009, the company has developed a full human antibody library using its proprietary RenMice® platform, launching the "Thousand Mice, Ten Thousand Antibodies" initiative in 2020 [3][17]. - The company has created over 1 million full human antibody sequences targeting more than 1,000 potential drug targets [3][17]. Financial Performance - In the first half of 2025, the company achieved revenue of 621 million yuan, a year-on-year increase of 51.3%, with a gross margin of 74.4% [3][30]. - The company is expected to achieve revenues of 14.2 billion yuan, 19.3 billion yuan, and 26.1 billion yuan from 2025 to 2027, with net profit growth rates of 323%, 103%, and 75% respectively [6][8]. Business Segments - The preclinical animal products and pharmacological services provide a stable foundation, with model animal sales reaching 274 million yuan in the first half of 2025, a 56% increase year-on-year [4][34]. - The antibody development business has become the core driver of performance, with 163 million yuan in revenue in the first half of 2025, a 38% increase year-on-year [5][34]. Market Position - The company has established partnerships with the top ten global pharmaceutical companies, leveraging its expertise in gene editing and model animals [4][21]. - The antibody drug market is experiencing rapid growth, with the global antibody drug market projected to reach 2.704 trillion USD in 2024, growing to 4.634 trillion USD by 2031 [47][49].

Investment Rating - The investment rating for Yum China (09987.HK) is "Outperform the Market" [5][22]. Core Insights - The company achieved a revenue of $3.206 billion in Q3 2025, representing a year-on-year increase of 4.4%. Operating profit rose by 7.8% to $400 million, driven by improved restaurant operational efficiency. However, net profit attributable to shareholders decreased by 5.1% to $282 million due to pre-tax investment losses of approximately $10 million [1][8]. - Same-store sales showed resilience with a 1% increase overall, while KFC and Pizza Hut reported increases of 2% and 1%, respectively. KFC's transaction volume increased by 3%, while Pizza Hut's transaction volume grew by 17% despite a decline in average ticket price [2][12]. - The company opened 536 new stores in Q3 2025, maintaining its annual target of 1,600 to 1,800 new stores. The total number of stores reached 17,514, with a growing proportion of franchise stores [3][14]. Financial Performance - For the fiscal year 2025, the company forecasts net profit of $927 million, with earnings per share (EPS) projected at $2.62. The price-to-earnings (PE) ratio is estimated to be 17.1x [4][21]. - The operating margin for Q3 2025 was 16.0% for KFC and 8.9% for Pizza Hut, reflecting a slight improvement year-on-year [1][8]. - The company plans to return approximately $1.5 billion to shareholders in 2025, with ongoing stock buybacks and dividends [21][22]. Operational Efficiency - The company has seen continuous improvement in operational efficiency, with employee benefits accounting for 26.2% of costs, while food costs decreased to 31.3% [3][18]. - The membership program has grown to 575 million members, with member sales accounting for 57% of total sales [14][21]. Future Outlook - The company is focusing on innovation with the expansion of its coffee brand and the introduction of new store formats, such as K pro, which has already reached 100 locations [21]. - The outlook for same-store sales remains positive, driven by ongoing product innovation and expansion plans [21][22].

2025 年 11 月 5 日 招银国际环球市场 | 睿智投资 | 公司更新 贝克微 (2149 HK) 贝克微 (2149 HK) - 纳入恒生半 整、四季度定价能力提升；重申 纳入恒生半导体指数、进行分销商战略性调整、四 "买入"评级 季度定价能力提升；重申"买入"评级 恒生指数正式将"恒生资讯科技业指数"更名为"恒生半导体行业主题指数"，并将 贝克微（2149 HK）纳入成份股，自 2025 年 11 月 7 日起生效。我们认为这将为 贝克微带来结构性利好，公司将有望受益于潜在被动资金流入提升市场流动性的 同时，吸引主动管理型基金的关注。重申"买入"评级；目标价维持 93 港元不变， 基于 26.6 倍 2025 年预测市盈率。 | (截至 12 月 31 日) | FY23A | FY24A | FY25E | FY26E | FY27E | | --- | --- | --- | --- | --- | --- | | 销售收入 (百万人民币) | 464 | 579 | 672 | 841 | 1,046 | | 同比增长 (%) | 31.6 | 24.8 | 16.1 | 25.1 | 24. ...

整、四季度定价能力提升；重申 纳入恒生半导体指数、进行分销商战略性调整、四 "买入"评级 季度定价能力提升；重申"买入"评级 恒生指数正式将"恒生资讯科技业指数"更名为"恒生半导体行业主题指数"，并将 贝克微（2149 HK）纳入成份股，自 2025 年 11 月 7 日起生效。我们认为这将为 贝克微带来结构性利好，公司将有望受益于潜在被动资金流入提升市场流动性的 同时，吸引主动管理型基金的关注。重申"买入"评级；目标价维持 93 港元不变， 基于 26.6 倍 2025 年预测市盈率。 | (截至 12 月 31 日) | FY23A | FY24A | FY25E | FY26E | FY27E | | --- | --- | --- | --- | --- | --- | | 销售收入 (百万人民币) | 464 | 579 | 672 | 841 | 1,046 | | 同比增长 (%) | 31.6 | 24.8 | 16.1 | 25.1 | 24.4 | | 毛利率 (%) | 55.4 | 53.0 | 52.4 | 52.4 | 52.4 | | 运营利润 (百万人民币) | 113.4 | ...

Investment Rating - The report assigns a "Buy" rating to New Oriental Education Technology (9901 HK) with a target price of HKD 55.00, indicating a potential upside of 19.9% from the current price of HKD 45.88 [4][8][15]. Core Insights - The report highlights that K12 education may accelerate, boosting shareholder returns and enhancing confidence in the company's growth prospects [2]. - Financial forecasts indicate a revenue growth trajectory, with expected revenues of USD 4.9 billion in 2025, growing to USD 6.875 billion by 2028, reflecting a compound annual growth rate (CAGR) of approximately 12% [3][16]. - The net profit is projected to increase from USD 372 million in 2025 to USD 792 million by 2028, with a notable increase in earnings per share (EPS) from USD 0.32 in 2025 to USD 0.45 in 2028 [3][16]. Financial Overview - Revenue (in million USD) is forecasted as follows: - 2024: 4,314 - 2025: 4,900 - 2026E: 5,413 - 2027E: 6,136 - 2028E: 6,875 - Year-on-year growth rates are expected to be 43.9% in 2024, 13.6% in 2025, and gradually declining to 12.0% by 2028 [3][16]. - Net profit (in million USD) projections are: - 2024: 310 - 2025: 372 - 2026E: 428 - 2027E: 481 - 2028E: 792 [3][16]. Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, assigning a price-to-earnings (P/E) ratio of 15x for K12 business and 8x for study abroad business, reflecting expected profit growth rates of +25% and -7% respectively [7][8]. - The target price was adjusted upwards to HKD 55.00 from a previous HKD 46.00, maintaining a "Buy" rating based on the strong demand and growth outlook for K12 education services [7][8].